dsm-firmenich presentan los primeros resultados mundiales comparando su novedosa formulación de CBD CBtru® con Epidiolex.
Este ensayo clínico de fase I muestra que CBtru® ofrece una biodisponibilidad equivalente o mejor que el estándar de referencia actual, con menos variabilidad entre sujetos y menor dependencia de los alimentos. Este sólido avance en la formulación podría transformar la administración de medicamentos con CBD con opciones de dosificación más convenientes y una mejor experiencia para el paciente.
Ponente:
Esta sesión dura 20 minutos.
Taste in pediatric drug formulations shapes acceptance and adherence. Here’s what formulators need to consider to support these vulnerable patients.
Discover how dsm-firmenich and ten23 health are transforming biologic formulation development through advanced excipient options.
Explore what newly published CBtru® pharmacokinetic data means for solid oral drug development—and why clinical evidence underpins meaningful innovation.
Have an idea for a new project, a groundbreaking innovation, or a need for expert services? Let’s talk.
Don’t just take our word for it. Discover how our solutions can support your product development journey.
Customized blends of functional ingredients in one single, efficient premix.
Streamline your product development process and get to market faster.
From trade shows to conferences and other industry events, find out where you can meet us next.
Talking Nutrition, Health & Care
Explore new science, consumer insights, industry news and more in our latest articles.
Discover educational whitepapers, webinars, publications and technical information.
Request samples, place orders and view product documentation.